December 24, 2013 | The Israeli Office of the Chief Scientist (OCS) has granted biomed company Cell Cure Neurosciences (a subsidiary of Bio Time) NIS 6.1 million. Cell Cure will use the funds to develop its OpRegen product, a cell-based treatment for age-related macular degeneration.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments